Lexitas Pharma Services has been named the newest Octane Preferred Advisor (OPA), expanding the resources available to founders, startups, and growth-stage companies developing ophthalmic drugs and devices within Octane’s innovation ecosystem.

According to the companies, the partnership brings together Octane’s network-building and growth support capabilities with Lexitas’ specialized ophthalmology clinical development expertise. As a full-service clinical research organization focused exclusively on ophthalmology, Lexitas has spent the past 15 years supporting sponsors across medical, scientific, regulatory, and clinical operations.

According to the company, Lexitas has supported more than 170 clinical trials spanning phase 1 through phase 4 development across anterior and posterior segment indications. Its global investigator network includes more than 700 sites, and the organization has enrolled more than 22,000 patients in anterior segment studies. The company also reports involvement in more than 40 posterior segment studies, including cell and gene therapy programs and rare disease research.

“At Lexitas, we partner with small to midsize biotech and medtech companies to help them advance ophthalmic innovations that can meaningfully improve patients’ lives,” said Jeanne Hecht, CEO and chairwoman of the board of Lexitas Pharma Services. “Partnering with Octane strengthens our ability to support early-stage and emerging organizations at a critical point in their journey, combining Octane’s expertise in helping founders build high-growth companies with Lexitas’ clinical development expertise. Together, we are helping innovators turn promising science into well-designed clinical programs built for long-term success.”

Lexitas said it has supported the clinical development of five FDA-approved ophthalmic products, including Xiidra, EyeSuvis, Inveltys, and Miebo. The company also reported meeting or exceeding all major study milestones during the past 24 months and maintaining a 99% clinical research associate retention rate.

The CRO offers end-to-end ophthalmic development services, including regulatory strategy, protocol design, medical monitoring, biometrics, medical and regulatory writing, project management, clinical operations, and integrated reading center services. Through a strategic partnership with NAMSA, the company also supports medical device development and regulatory programs, including combination products and device-focused innovations.

Lexitas has expanded its retinal and posterior segment capabilities through the acquisitions of Erie Retina Research, CASExERIE, and Element Erie, creating what the company describes as an integrated retina research ecosystem designed to strengthen site access, scientific expertise, and specialized development capabilities.